DOP2019000085A - ANTICUERPOS ANTIC1s Y MÉTODOS DE USO DE LOS MISMOS - Google Patents
ANTICUERPOS ANTIC1s Y MÉTODOS DE USO DE LOS MISMOSInfo
- Publication number
- DOP2019000085A DOP2019000085A DO2019000085A DO2019000085A DOP2019000085A DO P2019000085 A DOP2019000085 A DO P2019000085A DO 2019000085 A DO2019000085 A DO 2019000085A DO 2019000085 A DO2019000085 A DO 2019000085A DO P2019000085 A DOP2019000085 A DO P2019000085A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- antibodies
- present
- provides
- methods
- nucleic acids
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 102000016917 Complement C1 Human genes 0.000 abstract 1
- 108010028774 Complement C1 Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona anticuerpos que se enlazan de una forma específica con el componente de la vía del complemento C1s. La presente invención proporciona ácidos nucleicos que comprenden las secuencias de nucleótidos que codifican los anticuerpos antiC1s; y las células huéspedes que comprenden los ácidos nucleicos. La presente invención proporciona composiciones que comprenden los anticuerpos antiC1s. La presente invención proporciona los métodos de uso de los anticuerpos antiC1s.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407390P | 2016-10-12 | 2016-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2019000085A true DOP2019000085A (es) | 2019-07-31 |
Family
ID=61906346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2019000085A DOP2019000085A (es) | 2016-10-12 | 2019-04-08 | ANTICUERPOS ANTIC1s Y MÉTODOS DE USO DE LOS MISMOS |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20200048332A1 (es) |
| EP (1) | EP3525583A4 (es) |
| JP (3) | JP7069138B2 (es) |
| KR (2) | KR20240025715A (es) |
| CN (2) | CN116554320A (es) |
| AR (1) | AR110677A1 (es) |
| AU (2) | AU2017341766A1 (es) |
| BR (1) | BR112019007309A2 (es) |
| CA (1) | CA3040253A1 (es) |
| CL (1) | CL2019000975A1 (es) |
| CO (1) | CO2019004741A2 (es) |
| CR (1) | CR20190223A (es) |
| DO (1) | DOP2019000085A (es) |
| EA (1) | EA201990884A1 (es) |
| EC (1) | ECSP19033211A (es) |
| IL (2) | IL265957B2 (es) |
| MX (1) | MX2019004259A (es) |
| PE (1) | PE20191031A1 (es) |
| PH (1) | PH12019500789A1 (es) |
| SG (1) | SG11201903012RA (es) |
| TN (1) | TN2019000109A1 (es) |
| TW (1) | TWI773695B (es) |
| WO (1) | WO2018071676A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110818798A (zh) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| EP2914291B1 (en) | 2012-11-02 | 2022-02-23 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| HRP20230093T1 (hr) | 2015-04-06 | 2023-03-31 | Bioverativ Usa Inc. | Humanizirana anti-c1s protutijela i postupci njihove primjene |
| JP2023522102A (ja) * | 2020-04-20 | 2023-05-26 | ジェンザイム・コーポレーション | ヒト化抗補体Ｂｂ因子抗体およびその使用 |
| WO2022031978A1 (en) * | 2020-08-06 | 2022-02-10 | Bioverativ Usa Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| EP4337332A2 (en) | 2021-07-13 | 2024-03-20 | Mabwell Therapeutics Inc. | Anti-c1s antibodies and uses thereof |
| US20240117021A1 (en) | 2022-06-15 | 2024-04-11 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| ES2197145T3 (es) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | Transferencia de genes mediada por adenovirus al gastrointestinal. |
| WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| BR9407956A (pt) | 1993-10-25 | 1996-11-26 | Canji Inc | Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais |
| DK0889120T3 (da) | 1994-12-09 | 2002-07-22 | Imp College Innovations Ltd | Virulensgener i VGC2-regionen af Salmonella |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| DE69703974T2 (de) | 1996-10-17 | 2001-07-19 | Oxford Biomedica Ltd | Retrovirale vektoren |
| GB9622500D0 (en) | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| CA2467959C (en) | 2001-11-09 | 2009-03-10 | Robert M. Kotin | Production of adeno-associated virus in insect cells |
| US9715692B1 (en) | 2003-04-11 | 2017-07-25 | Facebook, Inc. | System for managing bids for pay-per-click search engines |
| WO2005056759A2 (en) * | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| ES2403055T3 (es) * | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1908797B1 (en) | 2005-07-05 | 2012-06-06 | Kaneka Corporation | Methacrylic resin composition |
| FR2897868B1 (fr) * | 2006-02-24 | 2012-08-31 | Lab Francais Du Fractionnement | Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii. |
| EP3023500B1 (en) | 2006-06-21 | 2020-02-12 | uniQure IP B.V. | Insect cells for the production of aav vectors |
| WO2009020640A2 (en) * | 2007-08-08 | 2009-02-12 | Swarmcast, Inc. | Media player plug-in installation techniques |
| EP2373687B1 (en) * | 2008-12-03 | 2016-10-26 | Genmab A/S | Igg4 antibody variants having modifications in the constant region |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| DK2561073T3 (en) | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| CN110818798A (zh) * | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| EP2914291B1 (en) * | 2012-11-02 | 2022-02-23 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| CA2899589C (en) * | 2013-01-31 | 2022-02-22 | Seoul National University R & Db Foundation | C5 antibody and method for preventing and treating complement-related diseases |
| HUE049769T2 (hu) * | 2013-05-23 | 2020-10-28 | Broteio Pharma B V | Humán komplemens C2 faktort kötõ kötõ molekulák és alkalmazásaik |
| AU2014287221C1 (en) * | 2013-07-09 | 2020-03-05 | Annexon, Inc. | Anti-complement factor C1q antibodies and uses thereof |
| HRP20230093T1 (hr) * | 2015-04-06 | 2023-03-31 | Bioverativ Usa Inc. | Humanizirana anti-c1s protutijela i postupci njihove primjene |
-
2017
- 2017-10-12 KR KR1020247005368A patent/KR20240025715A/ko active Application Filing
- 2017-10-12 CN CN202211195613.6A patent/CN116554320A/zh active Pending
- 2017-10-12 EA EA201990884A patent/EA201990884A1/ru unknown
- 2017-10-12 AU AU2017341766A patent/AU2017341766A1/en not_active Abandoned
- 2017-10-12 EP EP17859451.1A patent/EP3525583A4/en active Pending
- 2017-10-12 PE PE2019000814A patent/PE20191031A1/es unknown
- 2017-10-12 AR ARP170102855A patent/AR110677A1/es unknown
- 2017-10-12 BR BR112019007309A patent/BR112019007309A2/pt unknown
- 2017-10-12 WO PCT/US2017/056349 patent/WO2018071676A1/en unknown
- 2017-10-12 US US16/340,991 patent/US20200048332A1/en not_active Abandoned
- 2017-10-12 IL IL265957A patent/IL265957B2/en unknown
- 2017-10-12 MX MX2019004259A patent/MX2019004259A/es unknown
- 2017-10-12 SG SG11201903012RA patent/SG11201903012RA/en unknown
- 2017-10-12 CR CR20190223A patent/CR20190223A/es unknown
- 2017-10-12 CA CA3040253A patent/CA3040253A1/en active Pending
- 2017-10-12 IL IL308156A patent/IL308156A/en unknown
- 2017-10-12 JP JP2019519690A patent/JP7069138B2/ja active Active
- 2017-10-12 TW TW106134895A patent/TWI773695B/zh active
- 2017-10-12 TN TNP/2019/000109A patent/TN2019000109A1/en unknown
- 2017-10-12 CN CN201780074920.XA patent/CN110300520B/zh active Active
- 2017-10-12 KR KR1020197013448A patent/KR102638884B1/ko active IP Right Grant
-
2019
- 2019-04-08 DO DO2019000085A patent/DOP2019000085A/es unknown
- 2019-04-11 PH PH12019500789A patent/PH12019500789A1/en unknown
- 2019-04-11 CL CL2019000975A patent/CL2019000975A1/es unknown
- 2019-05-08 CO CONC2019/0004741A patent/CO2019004741A2/es unknown
- 2019-05-10 EC ECSENADI201933211A patent/ECSP19033211A/es unknown
-
2022
- 2022-04-28 JP JP2022073972A patent/JP7420864B2/ja active Active
- 2022-07-12 AU AU2022205174A patent/AU2022205174A1/en active Pending
-
2023
- 2023-07-07 US US18/349,027 patent/US20240076363A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002216A patent/JP2024038319A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19033211A (es) | ANTICUERPOS ANTIC1s Y MÉTODOS DE USO DE LOS MISMOS | |
| CY1124663T1 (el) | Αντιιικα παραγωγα ν4-υδροξυκυτιδινης | |
| CO2017011238A2 (es) | Anticuerpos anti-c1s humanizados | |
| BR112017003582A2 (pt) | anticorpos, composições e usos | |
| CO2017005842A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
| JOP20220242A1 (ar) | أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3 | |
| CO2017000300A2 (es) | Moléculas con especificidad para cd45 y cd79 | |
| BR112019012343A2 (pt) | anticorpos il-11ra | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| BR112017012679A2 (pt) | compostos imunomoduladores, seus usos, composição e kit | |
| CL2019000033A1 (es) | Variantes de xilanasa y polinucleótidos que las codifican. | |
| CL2017000576A1 (es) | Inhibidores de mk2 y sus usos | |
| EA201692425A1 (ru) | Модифицированные биополимеры и способы их получения и использования | |
| EA201500943A1 (ru) | Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
| CL2017000152A1 (es) | Derivados de isoindolinona | |
| BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
| CL2017003311A1 (es) | Proteínas de fijación multiespecífica. | |
| AR104923A1 (es) | SPODOPTERA FRUGIPERDA RESISTENTE A Vip3A | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| EA201690383A1 (ru) | НОВЫЕ АНТИТЕЛА К FC-γ-РЕЦЕПТОРУ IIB И ИХ ПРИМЕНЕНИЯ | |
| EA201790969A1 (ru) | Способы и композиции для безопасного и эффективного тромболизиса | |
| CL2018000201A1 (es) | Potenciamiento de la respuesta inmunológica en especies acuáticas | |
| AR103281A1 (es) | COMPOSICIONES, APARATOS Y MÉTODOS PARA DETERMINAR EL pH DE UNA SOLUCIÓN DE ANALITO |